Severe combined immunodeficinct (SCID) is a rough diagnosis, that leaves the immune system of a patient at high risk for serious infections. Orchard Therapeutics wants to develop a treatment SCID using the technology everyone is talking about these days– gene therapy.
They recently announced that they had raised $110 million to push the development along. They already have research underway, and more results are expected later on in 2018.
